Caldera Therapeutics Inc
Caldera Therapeutics is a clinical-stage biotechnology company developing first-in-class bispecific antibody therapeutics for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. The company’s lead program, CLD-423, targets the IL-23p19 and TL1A pathways and was in-licensed for global development and commercialization from Qyuns Therapeutics Co., Ltd.
Leadership & Board
- Current Number of Employees
- 18
- Current LinkedIn Followers
- 1,822
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $38M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $38M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Employee Trend
Caldera Therapeutics Inc had 18 employees as of October 12, 2026. The number of employees increased by 1 (5.88%) week-over-week.
Social Trend
Caldera Therapeutics Inc had 1,822 followers as of October 12, 2026. The number of followers increased by 11 (0.61%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 14, 2026 | Series A | $37.50M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Omega Funds | Series A |
| Janus Henderson Investors | Series A |
| Wellington Management | Series A |
Similar Companies
A snapshot of private companies similar to Caldera Therapeutics Inc, helping you discover and navigate related company profiles.
Related News and Analysis
